

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復旦張江生物醫藥股份有限公司
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code:1349)

INSIDE INFORMATION
IMPACT OF THE EPIDEMIC AND FINANCIAL INFORMATION ON THE
PROSPECTUS OF PROPOSED ISSUE OF A SHARES

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, of the Laws of Hong Kong).

References are made to the announcements of the Company dated 8 March 2019, 12 March 2019, 26 April 2019, 7 May 2019, 13 May 2019, 21 June 2019, 31 July 2019, 29 August 2019, 2 September 2019, 29 September 2019, 10 October 2019, 20 October 2019, 27 October 2019, 31 October 2019 and 19 March 2020, and the circulars of the Company dated 12 March 2019, 4 April 2019, 6 June 2019 and 4 March 2020 containing, among other things, related matters of the proposed initial public offering of A Shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the “**Shanghai Stock Exchange**”) by the Company (the “**Proposed Issue of A Shares**”). Unless otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circulars.

The full text of the Prospectus of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* for the Initial Public Offering of Shares and Listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (Submission Proof) (《上海復旦張江生物醫藥

股份有限公司首次公開發行股票並在科創板上市招股說明書（上會稿）》）(the “**Submission Proof Prospectus**”) issued by the Company in respect of listing application for A Shares was published on the website of the Shanghai Stock Exchange (<http://sse.com.cn/>) on 20 March 2020. Such document and the disclosure therein are prepared pursuant to the relevant laws, regulations and regulatory requirements in Mainland China and solely for the purpose of the Proposed Issue of A Shares.

The major financial data of the Group for the first quarter of 2020 and the comparative figures for the corresponding period are set out in the Submission Proof Prospectus. Such financial data is the result of the preliminary estimates by the management of the Company, which has not been audited or reviewed by the Company’s auditors, and it does not indicate that the Company can ultimately achieve such operating revenue and net profit, nor does it constitute a profit forecast of the Company.

Since the outbreak of the novel coronavirus epidemic (the “**Epidemic**”), the provinces and cities in China have adopted public health measures for emergencies, including but not limited to the limitation on the travel of citizens and implementation of conditional resumption of work after the Chinese New Year holidays, to curb the spread of the Epidemic. Although the Company has officially resumed operation in February 2020, the Epidemic has caused, among other things, the following impacts: (i) there is a significant decline in sales of the Group’s three main products. As the Group’s main products have to be used in hospitals for treatment, in addition to the logistic and transport restrictions, the suspension of relevant medical services leads to a relatively large impact on the terminal use. It is expected that after the epidemic situation is under control and the non-epidemic services of the hospitals across the country is fully recovered, the terminal use of the main products will have certain recovery growth; and (ii) the delivery from certain raw material suppliers of the Company is delayed due to limitation on resumption of work and transportation restrictions.

Considering the above impacts, based on the Company’s preliminary estimates and calculations, it is expected that the revenue in the first quarter of 2020 will be in the range of approximately RMB18.70 million to RMB36.50 million, with a year-on-year decrease from 78% to 56%. It is expected that net profit attributable to shareholders of the company is in the range of approximately RMB-19.80 million to RMB-7.34 million (in the same period of 2019: RMB4.9 million (unaudited)). It is expected that the net profit attributable to shareholders of the company after deducting non-recurring profit and loss is in the range of approximately RMB-21.3 million to RMB-10.35 million (in the same period of 2019: RMB1.47 million (unaudited)). In view that the revenue in the first quarter consistently accounts for a low proportion in the total revenue of the year, the decline in the results in the first quarter has limited impact on the annual results of 2020.

As at the date of the Submission Proof Prospectus, saved for the above impacts, the major operating conditions of the Company are normal. No material change in majors matters, including the Company’s operation model, purchasing model and purchasing price, sales

model and sales price, composition of major customers and suppliers and taxation policy as well as other matters that may affect the judgment of investors.

The above estimates of the Company do not constitute any guarantee of its future development, and may differ from the actual results of the Company due to various uncertainties. Such estimates do not constitute actual commitments to potential investors and shareholders of the Company. Potential investors and shareholders of the Company should be aware that inappropriate reliance on and usage of such information may expose to investment risks. The above English version of the major operation conditions of the Group is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

The Company has been notified by the Shanghai Stock Exchange that the Proposed Issue of A Shares will be reviewed in the review meeting of the Listing Committee of the Sci-tech Innovation Board to be held on 31 March 2020. Further announcement(s) regarding the progress of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement is for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By order of the Board
Wang Hai Bo
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)
Mr. Su Yong (Executive Director)
Mr. Zhao Da Jun (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Zhou Zhong Hui (Independent Non-executive Director)
Mr. Lam Yiu Kin (Independent Non-executive Director)
Mr. Xu Qing (Independent Non-executive Director)
Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

20 March 2020

** For identification purpose only*